U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Adenocarcinoma of esophagus

MedGen UID:
124636
•Concept ID:
C0279628
•
Neoplastic Process
Synonym: Esophageal adenocarcinoma
SNOMED CT: Adenocarcinoma of esophagus (276803003)
Modes of inheritance:
Not genetically inherited
MedGen UID:
988794
•Concept ID:
CN307044
•
Finding
Source: Orphanet
clinical entity without genetic inheritance.
See: This record
Not genetically inherited (Orphanet)
 
Monarch Initiative: MONDO:0005028
OMIM®: 614266
Orphanet: ORPHA99976

Definition

Esophageal adenocarcinoma (EAC) is a sub-type of esophageal carcinoma (EC; see this term) affecting the glandular cells of the lower esophagus at the junction with the stomach. [from ORDO]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVAdenocarcinoma of esophagus

Professional guidelines

PubMed

Spatiotemporal Distribution, Time to Treatment Outcome Clustering and Determinants of Esophageal Cancer in Ethiopia, a Scoping Study.
Beyen TK, Seife E, Gurara AM, McCormack V, Taye G, Addissie A
Cancer Control 2024 Jan-Dec;31:10732748241251712. doi: 10.1177/10732748241251712. PMID: 38716644Free PMC Article
Trends in Surgical Management of Esophageal Cancer.
Thakur B, Devkota M, Thapa A
J Nepal Health Res Counc 2023 Jul 20;20(4):868-874. doi: 10.33314/jnhrc.v20i4.4202. PMID: 37489669
Metabolic response evaluation by PET during neoadjuvant treatment for adenocarcinoma of the esophagus and esophagogastric junction.
Sendler A
Recent Results Cancer Res 2010;182:167-77. doi: 10.1007/978-3-540-70579-6_14. PMID: 20676880

Curated

UK NICE Guidance, NICE Guideline NG231, Barrett's oesophagus and stage 1 oesophageal adenocarcinoma: monitoring and management, 2023

Recent clinical studies

Etiology

Cancer Risk in Barrett's Esophagus: A Clinical Review.
Beydoun AS, Stabenau KA, Altman KW, Johnston N
Int J Mol Sci 2023 Mar 23;24(7) doi: 10.3390/ijms24076018. PMID: 37046992Free PMC Article
Barrett Esophagus: A Review.
Sharma P
JAMA 2022 Aug 16;328(7):663-671. doi: 10.1001/jama.2022.13298. PMID: 35972481
Epidemiology and prevention of oesophageal adenocarcinoma.
Ness-Jensen E
Scand J Gastroenterol 2022 Aug;57(8):891-895. Epub 2022 Mar 2 doi: 10.1080/00365521.2022.2042594. PMID: 35234549
Barrett's Esophagus.
Bujanda DE, Hachem C
Mo Med 2018 May-Jun;115(3):211-213. PMID: 30228724Free PMC Article
Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries.
Domper Arnal MJ, Ferrández Arenas Á, Lanas Arbeloa Á
World J Gastroenterol 2015 Jul 14;21(26):7933-43. doi: 10.3748/wjg.v21.i26.7933. PMID: 26185366Free PMC Article

Diagnosis

Advances in diagnosis and management of cancer of the esophagus.
Deboever N, Jones CM, Yamashita K, Ajani JA, Hofstetter WL
BMJ 2024 Jun 3;385:e074962. doi: 10.1136/bmj-2023-074962. PMID: 38830686
Management of Dysplastic Barrett's Esophagus and Early Esophageal Adenocarcinoma.
Cotton CC, Eluri S, Shaheen NJ
Gastroenterol Clin North Am 2022 Sep;51(3):485-500. Epub 2022 Aug 30 doi: 10.1016/j.gtc.2022.06.004. PMID: 36153106Free PMC Article
Barrett Esophagus: A Review.
Sharma P
JAMA 2022 Aug 16;328(7):663-671. doi: 10.1001/jama.2022.13298. PMID: 35972481
Gastric cancer.
Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H
Lancet 2016 Nov 26;388(10060):2654-2664. Epub 2016 May 5 doi: 10.1016/S0140-6736(16)30354-3. PMID: 27156933
Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries.
Domper Arnal MJ, Ferrández Arenas Á, Lanas Arbeloa Á
World J Gastroenterol 2015 Jul 14;21(26):7933-43. doi: 10.3748/wjg.v21.i26.7933. PMID: 26185366Free PMC Article

Therapy

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.
Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, Fernández MG, Li J, Lowery MA, Çil T, Cruz FM, Qin S, Luo S, Pan H, Wainberg ZA, Yin L, Bordia S, Bhagia P, Wyrwicz LS; KEYNOTE-859 investigators
Lancet Oncol 2023 Nov;24(11):1181-1195. Epub 2023 Oct 21 doi: 10.1016/S1470-2045(23)00515-6. PMID: 37875143
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.
Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D, Lordick F, Van Cutsem E, Gallego Plazas J, Huang J, Shen L, Oh SC, Sunpaweravong P, Soo Hoo HF, Turk HM, Oh M, Park JW, Moran D, Bhattacharya P, Arozullah A, Xu RH
Nat Med 2023 Aug;29(8):2133-2141. Epub 2023 Jul 31 doi: 10.1038/s41591-023-02465-7. PMID: 37524953Free PMC Article
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.
Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, Van Cutsem E, Xu RH, Aprile G, Xu J, Chao J, Pazo-Cid R, Kang YK, Yang J, Moran D, Bhattacharya P, Arozullah A, Park JW, Oh M, Ajani JA
Lancet 2023 May 20;401(10389):1655-1668. Epub 2023 Apr 15 doi: 10.1016/S0140-6736(23)00620-7. PMID: 37068504
Barrett Esophagus: A Review.
Sharma P
JAMA 2022 Aug 16;328(7):663-671. doi: 10.1001/jama.2022.13298. PMID: 35972481
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzis MV, Bruges R, Zander T, Pazo-Cid R, Hitre E, Feeney K, Cleary JM, Poulart V, Cullen D, Lei M, Xiao H, Kondo K, Li M, Ajani JA
Lancet 2021 Jul 3;398(10294):27-40. Epub 2021 Jun 5 doi: 10.1016/S0140-6736(21)00797-2. PMID: 34102137Free PMC Article

Prognosis

Cancer Risk in Barrett's Esophagus: A Clinical Review.
Beydoun AS, Stabenau KA, Altman KW, Johnston N
Int J Mol Sci 2023 Mar 23;24(7) doi: 10.3390/ijms24076018. PMID: 37046992Free PMC Article
The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates From GLOBOCAN 2020.
Morgan E, Soerjomataram I, Rumgay H, Coleman HG, Thrift AP, Vignat J, Laversanne M, Ferlay J, Arnold M
Gastroenterology 2022 Sep;163(3):649-658.e2. Epub 2022 Jun 4 doi: 10.1053/j.gastro.2022.05.054. PMID: 35671803
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer.
Shitara K, Ajani JA, Moehler M, Garrido M, Gallardo C, Shen L, Yamaguchi K, Wyrwicz L, Skoczylas T, Bragagnoli AC, Liu T, Tehfe M, Elimova E, Bruges R, Zander T, de Azevedo S, Kowalyszyn R, Pazo-Cid R, Schenker M, Cleary JM, Yanez P, Feeney K, Karamouzis MV, Poulart V, Lei M, Xiao H, Kondo K, Li M, Janjigian YY
Nature 2022 Mar;603(7903):942-948. Epub 2022 Mar 23 doi: 10.1038/s41586-022-04508-4. PMID: 35322232Free PMC Article
Oesophageal cancer.
Smyth EC, Lagergren J, Fitzgerald RC, Lordick F, Shah MA, Lagergren P, Cunningham D
Nat Rev Dis Primers 2017 Jul 27;3:17048. doi: 10.1038/nrdp.2017.48. PMID: 28748917Free PMC Article
Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries.
Domper Arnal MJ, Ferrández Arenas Á, Lanas Arbeloa Á
World J Gastroenterol 2015 Jul 14;21(26):7933-43. doi: 10.3748/wjg.v21.i26.7933. PMID: 26185366Free PMC Article

Clinical prediction guides

The single cell transcriptional landscape of esophageal adenocarcinoma and its modulation by neoadjuvant chemotherapy.
Croft W, Evans RPT, Pearce H, Elshafie M, Griffiths EA, Moss P
Mol Cancer 2022 Oct 17;21(1):200. doi: 10.1186/s12943-022-01666-x. PMID: 36253784Free PMC Article
Barrett Esophagus: A Review.
Sharma P
JAMA 2022 Aug 16;328(7):663-671. doi: 10.1001/jama.2022.13298. PMID: 35972481
The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates From GLOBOCAN 2020.
Morgan E, Soerjomataram I, Rumgay H, Coleman HG, Thrift AP, Vignat J, Laversanne M, Ferlay J, Arnold M
Gastroenterology 2022 Sep;163(3):649-658.e2. Epub 2022 Jun 4 doi: 10.1053/j.gastro.2022.05.054. PMID: 35671803
Prediction of Barrett's esophagus: are we there yet?
Gaddam S
Dis Esophagus 2018 Mar 1;31(3) doi: 10.1093/dote/dox147. PMID: 29346553
Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries.
Domper Arnal MJ, Ferrández Arenas Á, Lanas Arbeloa Á
World J Gastroenterol 2015 Jul 14;21(26):7933-43. doi: 10.3748/wjg.v21.i26.7933. PMID: 26185366Free PMC Article

Recent systematic reviews

Prevalence of Barrett's Esophagus and Esophageal Adenocarcinoma With and Without Gastroesophageal Reflux: A Systematic Review and Meta-analysis.
Saha B, Vantanasiri K, Mohan BP, Goyal R, Garg N, Gerberi D, Kisiel JB, Singh S, Iyer PG
Clin Gastroenterol Hepatol 2024 Jul;22(7):1381-1394.e7. Epub 2023 Oct 24 doi: 10.1016/j.cgh.2023.10.006. PMID: 37879525Free PMC Article
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.
Shah MA, Kennedy EB, Alarcon-Rozas AE, Alcindor T, Bartley AN, Malowany AB, Bhadkamkar NA, Deighton DC, Janjigian Y, Karippot A, Khan U, King DA, Klute K, Lacy J, Lee JJ, Mehta R, Mukherjee S, Nagarajan A, Park H, Saeed A, Semrad TJ, Shitara K, Smyth E, Uboha NV, Vincelli M, Wainberg Z, Rajdev L
J Clin Oncol 2023 Mar 1;41(7):1470-1491. Epub 2023 Jan 5 doi: 10.1200/JCO.22.02331. PMID: 36603169
The prevalence of viral agents in esophageal adenocarcinoma and Barrett's esophagus: a systematic review.
Kunzmann AT, Graham S, McShane CM, Doyle J, Tommasino M, Johnston B, Jamison J, James JA, McManus D, Anderson LA
Eur J Gastroenterol Hepatol 2017 Jul;29(7):817-825. doi: 10.1097/MEG.0000000000000868. PMID: 28252462
Risk of recurrence of Barrett's esophagus after successful endoscopic therapy.
Krishnamoorthi R, Singh S, Ragunathan K, A Katzka D, K Wang K, G Iyer P
Gastrointest Endosc 2016 Jun;83(6):1090-1106.e3. Epub 2016 Feb 20 doi: 10.1016/j.gie.2016.02.009. PMID: 26902843Free PMC Article
Antireflux Surgery and Risk of Esophageal Adenocarcinoma: A Systematic Review and Meta-analysis.
Maret-Ouda J, Konings P, Lagergren J, Brusselaers N
Ann Surg 2016 Feb;263(2):251-7. doi: 10.1097/SLA.0000000000001438. PMID: 26501714

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Curated

    • NICE, 2023
      UK NICE Guidance, NICE Guideline NG231, Barrett's oesophagus and stage 1 oesophageal adenocarcinoma: monitoring and management, 2023

    Reviews

    Related information

    • MeSH
      Related Medical Subject Headings
    • OMIM
      Related records in OMIM
    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...